Global Market Bulletin TV recently conducted an exclusive interview with Geert Kersten, the CEO of CEL-SCI Corporation (NASDAQ: CVM), a pioneering biotechnology company that is revolutionizing cancer immunotherapy. In this captivating discussion, host Leyla Gulen delves into the world of innovative cancer treatments and explores the groundbreaking advancements being made by CEL-SCI.
The focal point of the interview is CEL-SCI’s flagship product, Multikine, which has the potential to be a game-changer in the treatment of head and neck cancer. Geert Kersten, a visionary leader in the biotech industry, shares his insights on the science behind Multikine and its unique approach to activating the body’s immune system to fight cancer. The interview highlights the promising results observed in clinical trials, with Multikine significantly prolonging overall survival in head and neck cancer patients.
One significant milestone discussed in the interview is CEL-SCI’s poster presentation at the European Society for Radiotherapy and Oncology (ESTRO) 2023 Congress in Vienna, Austria. The histopathology analysis presented during the Head & Neck Cancer Session confirmed that Multikine not only improved 5-year survival but also demonstrated improved progression-free survival and significantly lowered the death rate compared to the standard of care.
Geert Kersten also touched upon the productive pre-submission meeting held with Health Canada’s regulator to determine the most effective regulatory path toward market approval. This highlights CEL-SCI’s commitment to bringing their innovative therapies to patients worldwide.
Geert Kersten, who has been leading CEL-SCI Corporation since 1995, brings a wealth of experience in cancer immunotherapy and has successfully navigated the volatile biotech industry for almost two decades. With a background in finance and law, Mr. Kersten envisions Multikine as a catalyst for positive change in the field of cancer treatment.
This thought-provoking interview is a must-watch for healthcare professionals, investors, and anyone interested in the latest advancements in cancer research. By subscribing to Global Market Bulletin TV, viewers gain invaluable insights into the world of immunotherapy and its potential to transform cancer treatment.
For more information about CEL-SCI Corporation and their innovative therapies, visit their official website at https://cel-sci.com. Stay informed about the latest industry developments by subscribing to Global Market Bulletin TV.